Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR101801 (Bosmolisib) in relapsed/refractory peripheral T-cell lymphoma
NCT07180771Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of bosmolisib in peripheral T-cell lymphoma (PTCL), sponsored by Boryung. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
bosmolisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07180771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180771.